(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of 22.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Akebia Therapeutics's revenue in 2025 is $184,909,000.On average, 3 Wall Street analysts forecast AKBA's revenue for 2025 to be $61,213,322,204, with the lowest AKBA revenue forecast at $53,630,237,711, and the highest AKBA revenue forecast at $68,731,798,281. On average, 3 Wall Street analysts forecast AKBA's revenue for 2026 to be $84,488,109,990, with the lowest AKBA revenue forecast at $72,482,238,019, and the highest AKBA revenue forecast at $104,082,581,807.
In 2027, AKBA is forecast to generate $86,166,352,982 in revenue, with the lowest revenue forecast at $80,524,147,318 and the highest revenue forecast at $89,217,393,489.